Don't get left behind! The modernized ClinicalTrials.gov is coming. Check it out now.
Say goodbye to ClinicalTrials.gov!
The new site is coming soon - go to the modernized ClinicalTrials.gov
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05243550
Recruitment Status : Active, not recruiting
First Posted : February 17, 2022
Last Update Posted : May 9, 2023
Sponsor:
Information provided by (Responsible Party):
UroGen Pharma Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : April 26, 2023
Estimated Study Completion Date : February 2028